MIRA Pharmaceuticals, Inc.

MIRA Healthcare Drug Manufacturers General

In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 50.8%, each against the same quarter a year earlier.

0.63 0.03 −4.55%
Market cap
$27.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Current Ratio

+8 more quarters

90.56 15.75 82.13 200.19
Net Debt/EBITDA
5.72 1.89 8.52 7.02
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.05 0.19 1.04 1.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(0.06) (0.05) (0.03) (0.03)
Cash per Share
0.39 0.47 0.22 0.19
Shareholders Equity per Share
0.39 0.44 0.22 0.19
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
0.39 0.44 0.22 0.19
Free Cash Flow
(1.10) (1.14) (1.20) (1.21)
Working Capital
7.51 10.36 9.31 8.13
Net Current Asset Value
7.51 10.36 9.31 8.13
Other line items
Quick Ratio
89.82 15.71 81.94 198.86
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.06) (0.05) (0.03) (0.03)
Capex per Share
0.00 0.00 0.00 0.00
Average Payables
0.39 0.43 0.07 0.17
Average Assets
5.95 7.01 5.43 4.54
Average Common Equity
5.56 6.30 5.32 4.37

Fold the line items

Columns are period end dates